

#### 12/10/2021

Fisher & Paykel Healthcare Limited Reena Daken Regulatory Affairs Market Manager 15 Maurice Paykel Place, East Tamaki Auckland, 2013 New Zealand

Re: K211560

Trade/Device Name: Airvo Nebulizer Adapter Regulation Number: 21 CFR 868.5630 Regulation Name: Nebulizer Regulatory Class: Class II Product Code: CAF Dated: November 12, 2021 Received: November 12, 2021

Dear Reena Daken:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Brandon Blakely
Assistant Director
DHT1C: Division of Sleep Disordered
Breathing, Respiratory and
Anesthesia Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

## **Indications for Use**

510(k) Number *(if known)* K211560

Device Name Airvo Nebulizer Adapter

| Indications for | Use | (Describe) |
|-----------------|-----|------------|
|-----------------|-----|------------|

Indications for use - AIRVO nebulizer adapter:

When used with a nebulizer:

| The nebulizer adapter is a medical device accessory for single-patient use to facilitate aerosolization of Albuterol sulfate |
|--|
| for inhalation to adult patients receiving high-flow humidified breathing gases via tracheostomy patient interface.          |
| Intended for use by healthcare professionals in hospitals or long-term care facilities.                                      |

When used without a nebulizer:

For use in hospitals and long-term care facilities, for the delivery of humidified respiratory gases to patients via nasal, tracheostomy and mask interfaces.

| Type of Use | (Select one | or both, | as applicable) |
|-------------|-------------|----------|----------------|
|-------------|-------------|----------|----------------|

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov* 

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary

As Required by 21 CFR 807.92(c)

# I. SUBMITTER

| Company Name and Address | Fisher & Paykel Healthcare Limited<br>15 Maurice Paykel Place<br>East Tamaki<br>Auckland 2013, New Zealand<br>Telephone: +64 9 574 0100 |
|--------------------------|---|
| Contact Person           | Reena Daken<br>Regulatory Affairs Manager<br>Telephone: +64 9 574 0100<br>Email: reena.daken@fphcare.co.nz                              |
| Date Prepared            | 10 December 2021  |

## **II. SUBJECT DEVICE**

| Name of Device      | Airvo Nebulizer Adapter              |
|---------------------|--------------------------------------|
| Common/Usual Name   | Airvo Nebulizer Adapter              |
| Classification Name | Nebulizer (Direct Patient Interface) |
|                     | Class II (21 CFR §868.5630)          |
| Product Code        | CAF                                  |

## **III. PREDICATE DEVICE**

Aeroneb Solo Nebulizer System / Aeroneb Solo Adapter (K133360)

# **IV. DEVICE DESCRIPTION**

The Airvo Nebulizer Adapter (hereafter named "nebulizer adapter") is a single use accessory device designed to facilitate aerosolization of a physician-prescribed solution for inhalation to patients receiving high flow humidified breathing gases. The nebulizer adapter is a prescription-only accessory device, provided in a non-sterile state.

The nebulizer adapter is kitted with the AirSpiral tube and MR290 humidification chamber cleared in K162553, to be used in conjunction with Airvo series humidifiers (K131895) along with patient interfaces cleared in K162553.

The device is labelled for use with Salbutamol/ Albuterol only.

## V. INDICATIONS FOR USE

#### Indications for use - AIRVO nebulizer adapter:

When used with a nebulizer:

The nebulizer adapter is a medical device accessory for single-patient use to facilitate aerosolization of Albuterol sulfate for inhalation to adult patients receiving high-flow humidified breathing gases via tracheostomy patient interface. Intended for use by healthcare professionals in hospitals or long-term care facilities.

When used without a nebulizer:

For use in hospitals and long-term care facilities, for the delivery of humidified respiratory gases to patients via nasal, tracheostomy and mask interfaces.

# VI. NON-CLINICAL PERFORMANCE DATA

The following tests were completed:

- Shelf life simulation was based on ASTM F1980-07, and ISO 291:2008(E).
- Transportation simulation was based on ISTA 2A Packaged-Products weighing 150lb (68kg) or less.
- Additional performance testing has also been completed to confirm the safety and effectiveness of the nebulizer adapter.
  - Nebulizer performance testing to demonstrate that nebulizing performance is equivalent when using an Airvo nebulizer adapter to when using an Aerogen T-piece.
  - Testing to verify that the Airvo system meets the requirements of ISO 80601-2-74 when used with the nebulizer adapter
  - Testing to establish that the usability of the Airvo nebulizer adapter is safe and effective for its intended users, uses, and use environments.
  - Testing to verify that the wear and stresses associated with the distribution of the packaged product does not cause damage to either the product or packaging.
  - Testing to verify that nebulization via the Airvo nebulizer port does not adversely affect the Airvo 2 or AirSpiral tube.
  - Testing to verify that the port cap will stay in place and not fall out of the nebulizer port during use with the Airvo 2 system
  - Testing to measure the total volume of condensate, with the potential to reach the patient, that forms over 24 hours in an Airvo system when used with the Airvo nebulizer adapter.

The Airvo Nebulizer Adapter has been tested to applicable requirements of the following standards:

- ISO 80601-2-74 Medical electrical equipment Part 2-74: Particular requirements for basic safety and essential performance of respiratory humidifying equipment
- ISO 10993-1:2018, Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process.
- ISO 18562-1:2017 Biocompatibility evaluation of breathing gas pathways in healthcare applications, Part 1: Evaluation and testing within a risk management process.

| VII. | COMPARISON OF TECHNOLOGICAL CHARATCERISTICS WITH THE PREDICATE DEVICE |  |
|------|---|--|
|------|---|--|

| Feature/Function  | Subject Device<br>Nebulizer Adapter  | Predicate Device<br>Aerogen T-piece (cleared as part of Aerogen<br>Solo system K133360)  | Comments   |
|---|--|--|--|
| Product Code<br>Device Classification<br>Classification Panel | CAF<br>Class II (21 CFR §868.5630)<br>Anesthesiology   | CAF<br>Class II (21 CFR §868.5630)<br>Anesthesiology   | Identical  |
| Intended Use  | Used for attaching a nebulizer system to<br>a breathing circuit to allow the delivery<br>of nebulized medication   | Used for attaching a nebulizer system to a breathing<br>circuit to allow the delivery of nebulized<br>medication   | Identical  |
| Indications for Use   | Indications for use - AIRVO nebulizeradapter:When used with a nebulizer:The nebulizer adapter is a medicaldevice accessory for single-patient useto facilitate aerosolization of Albuterolsulfate for inhalation to adult patientsreceiving high-flow humidifiedbreathing gases via tracheostomy patientinterface. Intended for use by healthcareprofessionals in hospitals or long-termcare facilities.When used without a nebulizer:For use in hospitals and long-term carefacilities, for the delivery of humidifiedrespiratory gases to patients via nasal,tracheostomy and mask interfaces. | As the Aerogen T-piece was cleared as part of the<br>Aerogen Solo system K133360, it does not have its<br>own Indications for Use statement.<br>The Indications for Use statement of the Aerogen<br>Solo system is:<br>The Aerogen Solo Nebulizer System is a portable<br>medical device for single patient use that is<br>intended to aerosolize physician-prescribed<br>solutions for inhalation to patients on and off<br>ventilation or other positive pressure breathing<br>assistance. | Equivalent to predicate<br>Both, the subject device and predicate have the same<br>general intended use: to be used with an Aerogen<br>Solo nebulizer to introduce nebulized drug into a<br>respiratory breathing circuit, however, only<br>Salbutamol/Albuterol can be delivered through this<br>adapter. |
| Availability  | Prescription use.<br>(Part 21 CFR 801 Subpart D)   | Prescription use.<br>(Part 21 CFR 801 Subpart D)   | Identical  |

| Feature/Function   | Subject Device<br>Nebulizer Adapter                       | Predicate Device<br>Aerogen T-piece (cleared as part of Aerogen<br>Solo system K133360)                              | Comments   |
|--|---|--|--|
| Application  | Nebulization within a humidified high flow therapy system | Nebulization within a non-specific breathing support system  | Equivalent to predicate.<br>The subject device functions within a subset of the<br>predicate device.   |
| Environment of Use   | Hospital  | Hospital   | Identical  |
| Connection to breathing circuit  | Airvo nebulizer adapter has proprietary connectors        | T-piece with 22mm ISO medical tapers (Male inlet and Female outlet)  | The subject device is proprietary to the Airvo system<br>while the predicate is a T-piece able to be connected<br>to any breathing circuit.  |
| Nebulizer port orientation when<br>attached to a humidification<br>chamber | Nebulizer port at 15° above horizontal                    | Nebulizer port at 15° above horizontal   | Identical  |
| Position in circuit  | Wet side of humidification chamber in single-limb circuit | End of inspiratory limb in a dual-limb circuit or<br>dry side of humidification chamber in a single-<br>limb circuit | The subject device functions within a subset of the<br>predicate device (subject device has no dual-limb<br>configuration). Comparative testing done on the<br>two systems shows equivalence between the drug<br>delivery to the patient on both systems, when<br>predicate is tested with "dry side of humidification<br>chamber" nebulizer positioning as per predicate<br>Instructions For Use. |
| Sterility  | Device not provided sterile                               | Device not provided sterile  | Identical  |
| Reusability  | Single use  | Single use   | Identical  |
| Maximum duration of use with nebulized drugs                               | 7 days continuous use                                     | 7 days continuous use  | Identical  |
| Shelf life   | 3 years   | Not specified  | Shelf life is not specified for the predicate  |

| Feature/Function  | Subject Device<br>Nebulizer Adapter  | Predicate Device<br>Aerogen T-piece (cleared as part of Aerogen<br>Solo system K133360)  | Comments  |
|---|--|--|---|
| Flow path gas flow range when<br>nebulizing albuterol via a<br>tracheostomy                   | 10 – 30 L/min  | Not defined  | Flow range is not defined for predicate device  |
| Flow path gas pressure range  | Less than 25 cm H <sub>2</sub> O   | Less than 90 cm H <sub>2</sub> O   | The subject device's pressure range is within the pressure range of the predicate                               |
| On-label Drugs for Delivery   | Salbutamol/Albuterol only  | General purpose nebulizer  | The on-label drugs for use with the subject device is<br>a subset of the drugs for use on the predicate device. |
| Respirable dose (1 - 5 µm)<br>when nebulizing albuterol via a<br>tracheostomy                 | From 2500 μg nebule:<br>10 L/min – 1293.1 μg<br>20 L/min – 949.5 μg<br>30 L/min – 612.6 μg | From 2500 μg nebule:<br>10 L/min – 1339.3 μg<br>20 L/min – 991.8 μg<br>30 L/min – 624.4 μg<br>When nebulizer placed on dry side of<br>humidification chamber | Equivalent to predicate   |
| Median Mass Aerodynamic<br>Diameter (MMAD) when<br>nebulizing albuterol via a<br>tracheostomy | 10 L/min – 2.80 μm<br>20 L/min – 2.73 μm<br>30 L/min – 2.54 μm                             | 10 L/min – 2.55 μm<br>20 L/min – 2.63 μm<br>30 L/min – 2.59 μm<br>When nebulizer placed on dry side of<br>humidification chamber                             | Equivalent to predicate   |
| Compatibility with Tracheal<br>Patient Interface  | Yes, Trache patient interface (OPT970)   | Yes, when patient intubated through a trachea interface  | Equivalent to predicate   |

### VIII. ACCESSORIES

| Port Cap Open and Nebulizer Fitted  | Port Cap Closed   |
|---|---|
| <ul> <li>When the Port Cap is OPEN, and an Aerogen Solo nebulizer is fitted and used to deliver nebulized albuterol, the Airvo Nebulizer Adapter will be compatible with the following patient interface:</li> <li>OPT970 tracheostomy interface</li> </ul> | <ul> <li>When the Port Cap is CLOSED, and only warmed/humidified air/oxygen mixtures are delivered to the patient WITHOUT nebulized medication, the Airvo Nebulizer Adapter will be compatible with the following patient interfaces:</li> <li>OPT970 tracheostomy interface</li> <li>OPT942/OPT944/OPT946 Nasal Cannulas</li> <li>OPT316/OPT318 Nasal Cannulas</li> <li>OPT980 Mask Interface Adapter</li> </ul> |

# IX. CONCLUSIONS

The comparison of features, performance, and intended use demonstrate that the Airvo nebulizer adapter is substantially equivalent to the predicate Aerogen T-piece (K133360). In addition, performance testing of the nebulizer adapter was completed to determine that the differences between the subject device and the predicate device do not raise new questions of safety or effectiveness. These tests demonstrate substantial equivalence of the nebulizer adapter to the predicate device.